{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T21:10:55Z","timestamp":1793481055511,"version":"4.5.0"},"reference-count":182,"publisher":"European Respiratory Society (ERS)","issue":"178","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["publications.ersnet.org"],"crossmark-restriction":true},"short-container-title":["Eur Respir Rev"],"accepted":{"date-parts":[[2025,10,5]]},"published-print":{"date-parts":[[2025,10]]},"abstract":"<jats:p>COPD is a heterogeneous, progressive inflammatory airway disease, with patients presenting with a wide variety of symptoms, comorbid conditions and underlying pathophysiology. Smoking is a major contributing factor to disease burden, alongside other environmental and patient-related risk factors. Airway inflammation is consistently present in COPD and is implicated in disease pathogenesis and progression. The airway epithelium functions as an active physiochemical barrier, protecting the lungs from pathogens and airborne environmental triggers, and as an immune organ that coordinates immunological activity in response to pollutant, bacterial, viral or allergen exposure. Inhalation of cigarette smoke and other airborne triggers can damage bronchial epithelial cells, leading to exaggerated inflammatory responses and airway remodelling. Airway inflammation in COPD, including neutrophilic and eosinophilic phenotypes, is mediated by the epithelium and epithelial cell-derived cytokines. Improving our understanding of epithelial-related inflammation in COPD is essential for the identification of novel biomarkers, stratification of patients, development of targeted therapeutics and creation of personalised treatment strategies. Here, we review the current understanding of the role of the airway epithelium in COPD pathogenesis, providing an overview of the pathological changes to the epithelium and the role of the epithelial-derived cytokines in driving different inflammatory phenotypes. We then consider biomarkers related to epithelial function in COPD and discuss how the epithelium might be targeted by novel COPD therapies.<\/jats:p>","DOI":"10.1183\/16000617.0110-2025","type":"journal-article","created":{"date-parts":[[2025,12,17]],"date-time":"2025-12-17T09:30:24Z","timestamp":1765963824000},"page":"250110","update-policy":"https:\/\/doi.org\/10.1183\/ers-crossmark-policy","source":"Crossref","is-referenced-by-count":16,"title":["A translational view of airway epithelial dysfunction in COPD"],"prefix":"10.1183","volume":"34","author":[{"given":"Christopher E.","family":"Brightling","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9993-2478","authenticated-orcid":false,"given":"Mona","family":"Bafadhel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"MeiLan K.","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Francois","family":"Papon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Klaus F.","family":"Rabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7801-5040","authenticated-orcid":false,"given":"Paola","family":"Rogliani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dave","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"81","published-online":{"date-parts":[[2025,12,17]]},"reference":[{"key":"2025121701301690000_34.178.250110.1","unstructured":"Global Initiative for Chronic Obstructive Lung Disease (GOLD) . Global Strategy for the Diagnosis, Management and Prevention of COPD. 2024. Date last accessed: 13 June 2024. https:\/\/goldcopd.org\/2024-gold-report\/"},{"key":"2025121701301690000_34.178.250110.2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(22)01273-9"},{"key":"2025121701301690000_34.178.250110.3","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1111\/resp.14474","article-title":"Is FeNOtyping in COPD the path to precision medicine?","volume":"28","author":"Flynn","year":"2023","journal-title":"Respirology"},{"key":"2025121701301690000_34.178.250110.4","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(09)61303-9"},{"key":"2025121701301690000_34.178.250110.5","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00651-2019"},{"key":"2025121701301690000_34.178.250110.6","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1111\/resp.14007","article-title":"Natural history and mechanisms of COPD","volume":"26","author":"Lange","year":"2021","journal-title":"Respirology"},{"key":"2025121701301690000_34.178.250110.7","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1172\/JCI124606","article-title":"Epithelial cell-derived cytokines: more than just signaling the alarm","volume":"129","author":"Roan","year":"2019","journal-title":"J Clin Invest"},{"key":"2025121701301690000_34.178.250110.8","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1164\/rccm.202303-0455CI","article-title":"Targeting type 2 inflammation and epithelial alarmins in chronic obstructive pulmonary disease: a biologics outlook","volume":"208","author":"Rabe","year":"2023","journal-title":"Am J Respir Crit Care Med"},{"key":"2025121701301690000_34.178.250110.9","doi-asserted-by":"publisher","DOI":"10.1183\/16000617.0112-2021"},{"key":"2025121701301690000_34.178.250110.10","doi-asserted-by":"publisher","DOI":"10.1513\/pats.200907-067DP"},{"key":"2025121701301690000_34.178.250110.11","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01397-2023"},{"key":"2025121701301690000_34.178.250110.12","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1016\/j.jaci.2020.04.010","article-title":"Epithelial barriers in allergy and asthma","volume":"145","author":"Hellings","year":"2020","journal-title":"J Allergy Clin Immunol"},{"key":"2025121701301690000_34.178.250110.13","doi-asserted-by":"publisher","DOI":"10.1242\/dev.083840"},{"key":"2025121701301690000_34.178.250110.14","doi-asserted-by":"publisher","DOI":"10.1016\/j.stem.2011.04.003"},{"key":"2025121701301690000_34.178.250110.15","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-018-0393-7"},{"key":"2025121701301690000_34.178.250110.16","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-018-0394-6"},{"key":"2025121701301690000_34.178.250110.17","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201408-1492PP"},{"key":"2025121701301690000_34.178.250110.18","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1201658"},{"key":"2025121701301690000_34.178.250110.19","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a028241"},{"key":"2025121701301690000_34.178.250110.20","doi-asserted-by":"publisher","DOI":"10.3389\/fphys.2021.691227"},{"key":"2025121701301690000_34.178.250110.21","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2010.05.046"},{"key":"2025121701301690000_34.178.250110.22","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.202208-1459ED"},{"key":"2025121701301690000_34.178.250110.23","doi-asserted-by":"publisher","DOI":"10.1152\/ajplung.00192.2022"},{"key":"2025121701301690000_34.178.250110.24","unstructured":"Ontology Lookup Service (OLS) . Respiratory tract suprabasal cell. 2024. Date last accessed: 23 September 2024. https:\/\/purl.obolibrary.org\/obo\/CL_4033048"},{"key":"2025121701301690000_34.178.250110.25","doi-asserted-by":"publisher","DOI":"10.1186\/s12931-022-02042-5"},{"key":"2025121701301690000_34.178.250110.26","doi-asserted-by":"crossref","first-page":"14789","DOI":"10.3390\/ijms241914789","article-title":"Transcriptional regulation of airway epithelial cell differentiation: insights into the Notch pathway and beyond","volume":"24","author":"Cumplido-Laso","year":"2023","journal-title":"Int J Mol Sci"},{"key":"2025121701301690000_34.178.250110.27","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201911-2199oc"},{"key":"2025121701301690000_34.178.250110.28","doi-asserted-by":"publisher","DOI":"10.3390\/cells9092090"},{"key":"2025121701301690000_34.178.250110.29","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01307-2022"},{"key":"2025121701301690000_34.178.250110.30","doi-asserted-by":"crossref","unstructured":"Romano Ibarra GS , Lei L , Yu W , et al. IL-13 induces loss of CFTR in ionocytes and reduces airway epithelial fluid absorption. J Clin Invest 2024; 134: e181995. doi:10.1172\/JCI181995","DOI":"10.1172\/JCI181995"},{"key":"2025121701301690000_34.178.250110.31","doi-asserted-by":"publisher","DOI":"10.1165\/rcmb.2013-0199OC"},{"key":"2025121701301690000_34.178.250110.32","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1126\/science.adh5483","article-title":"Neuroendocrine cells initiate protective upper airway reflexes","volume":"384","author":"Seeholzer","year":"2024","journal-title":"Science"},{"key":"2025121701301690000_34.178.250110.33","doi-asserted-by":"crossref","first-page":"dmm050620","DOI":"10.1242\/dmm.050620","article-title":"Investigating pulmonary neuroendocrine cells in human respiratory diseases with airway models","volume":"17","author":"Candeli","year":"2024","journal-title":"Dis Model Mech"},{"key":"2025121701301690000_34.178.250110.34","doi-asserted-by":"publisher","DOI":"10.1113\/JP282307"},{"key":"2025121701301690000_34.178.250110.35","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2020.03.005"},{"key":"2025121701301690000_34.178.250110.36","doi-asserted-by":"publisher","DOI":"10.1038\/nm.1946"},{"key":"2025121701301690000_34.178.250110.37","doi-asserted-by":"publisher","DOI":"10.1513\/pats.200805-041HR"},{"key":"2025121701301690000_34.178.250110.38","doi-asserted-by":"publisher","DOI":"10.1378\/chest.12-1766"},{"key":"2025121701301690000_34.178.250110.39","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1080\/15412555.2021.1963695","article-title":"Dysfunctional bronchial cilia are a feature of chronic obstructive pulmonary disease (COPD)","volume":"18","author":"Thomas","year":"2021","journal-title":"COPD"},{"key":"2025121701301690000_34.178.250110.40","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201406-1167LE"},{"key":"2025121701301690000_34.178.250110.41","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2012.04.001"},{"key":"2025121701301690000_34.178.250110.42","doi-asserted-by":"publisher","DOI":"10.1016\/S1357-2725(02)00083-3"},{"key":"2025121701301690000_34.178.250110.43","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2559.2004.01952.x"},{"key":"2025121701301690000_34.178.250110.44","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23020985"},{"key":"2025121701301690000_34.178.250110.45","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1106955"},{"key":"2025121701301690000_34.178.250110.46","doi-asserted-by":"crossref","first-page":"317","DOI":"10.4046\/trd.2017.0080","article-title":"Small airway disease in patients with chronic obstructive pulmonary disease","volume":"80","author":"Singh","year":"2017","journal-title":"Tuberc Respir Dis"},{"key":"2025121701301690000_34.178.250110.47","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201311-1982LE"},{"key":"2025121701301690000_34.178.250110.48","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0018378"},{"key":"2025121701301690000_34.178.250110.49","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.202008-3198OC"},{"key":"2025121701301690000_34.178.250110.50","doi-asserted-by":"crossref","first-page":"762878","DOI":"10.3389\/fmed.2021.762878","article-title":"Dysregulated cell signaling in pulmonary emphysema","volume":"8","author":"Lin","year":"2022","journal-title":"Front Med"},{"key":"2025121701301690000_34.178.250110.51","doi-asserted-by":"crossref","first-page":"109540","DOI":"10.1016\/j.cellsig.2020.109540","article-title":"Lung epithelium damage in COPD \u2013 an unstoppable pathological event?","volume":"68","author":"Hadzic","year":"2020","journal-title":"Cell Signal"},{"key":"2025121701301690000_34.178.250110.52","doi-asserted-by":"publisher","DOI":"10.1183\/16000617.0144-2022"},{"key":"2025121701301690000_34.178.250110.53","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.ejim.2024.05.011","article-title":"Towards precision medicine in COPD: targeting type 2 cytokines and alarmins","volume":"125","author":"Varricchi","year":"2024","journal-title":"Eur J Intern Med"},{"key":"2025121701301690000_34.178.250110.54","doi-asserted-by":"crossref","first-page":"437","DOI":"10.3390\/biomedicines11020437","article-title":"TSLP and HMGB1: inflammatory targets and potential biomarkers for precision medicine in asthma and COPD","volume":"11","author":"Furci","year":"2023","journal-title":"Biomedicines"},{"key":"2025121701301690000_34.178.250110.55","doi-asserted-by":"crossref","first-page":"975914","DOI":"10.3389\/fimmu.2022.975914","article-title":"Epithelial cell alarmin cytokines: frontline mediators of the asthma inflammatory response","volume":"13","author":"Duchesne","year":"2022","journal-title":"Front Immunol"},{"key":"2025121701301690000_34.178.250110.56","first-page":"e136166","article-title":"Epithelial IL-33 appropriates exosome trafficking for secretion in chronic airway disease","volume":"6","author":"Katz-Kiriakos","year":"2021","journal-title":"JCI Insight"},{"key":"2025121701301690000_34.178.250110.57","first-page":"A7799","article-title":"Pyroptosis is a novel mechanism of IL-33 release from airway epithelial cells","volume":"197","author":"Bernard","year":"2018","journal-title":"Am J Respir Crit Care Med"},{"key":"2025121701301690000_34.178.250110.58","doi-asserted-by":"publisher","DOI":"10.1111\/imr.12619"},{"key":"2025121701301690000_34.178.250110.59","doi-asserted-by":"publisher","DOI":"10.1038\/s41590-022-01255-6"},{"key":"2025121701301690000_34.178.250110.60","doi-asserted-by":"publisher","DOI":"10.1111\/imr.12552"},{"key":"2025121701301690000_34.178.250110.61","doi-asserted-by":"crossref","first-page":"2601","DOI":"10.3389\/fimmu.2018.02601","article-title":"The pleiotropic immunomodulatory functions of IL-33 and its implications in tumor immunity","volume":"9","author":"Afferni","year":"2018","journal-title":"Front Immunol"},{"key":"2025121701301690000_34.178.250110.62","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.1056838"},{"key":"2025121701301690000_34.178.250110.63","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms9327"},{"key":"2025121701301690000_34.178.250110.64","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.02210-2022"},{"key":"2025121701301690000_34.178.250110.65","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2015.02.011"},{"key":"2025121701301690000_34.178.250110.66","doi-asserted-by":"publisher","DOI":"10.1172\/JCI65570"},{"key":"2025121701301690000_34.178.250110.67","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1186\/s12890-021-01423-8","article-title":"Association between plasma interleukin-33 level and acute exacerbation of chronic obstructive pulmonary disease","volume":"21","author":"Joo","year":"2021","journal-title":"BMC Pulm Med"},{"key":"2025121701301690000_34.178.250110.68","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00347-2024"},{"key":"2025121701301690000_34.178.250110.69","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1164\/rccm.202210-1881OC","article-title":"IL-33 expression is lower in current smokers at both transcriptomic and protein levels","volume":"208","author":"Faiz","year":"2023","journal-title":"Am J Respir Crit Care Med"},{"key":"2025121701301690000_34.178.250110.70","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1186\/s12931-018-0807-y","article-title":"The association between airway eosinophilic inflammation and IL-33 in stable non-atopic COPD","volume":"19","author":"Tworek","year":"2018","journal-title":"Respir Res"},{"key":"2025121701301690000_34.178.250110.71","doi-asserted-by":"publisher","DOI":"10.1038\/s12276-018-0116-z"},{"key":"2025121701301690000_34.178.250110.72","doi-asserted-by":"publisher","DOI":"10.1016\/B978-0-12-404717-4.00004-4"},{"key":"2025121701301690000_34.178.250110.73","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.181.4.2790"},{"key":"2025121701301690000_34.178.250110.74","first-page":"4942","article-title":"Effect of TSLP on the function of platelets and IL-25 in chronic obstructive pulmonary disease","volume":"12","author":"Wu","year":"2019","journal-title":"Int J Clin Exp Med"},{"key":"2025121701301690000_34.178.250110.75","doi-asserted-by":"crossref","first-page":"108421","DOI":"10.1016\/j.clim.2020.108421","article-title":"Epithelial-macrophage-dendritic cell interactions impact alarmins expression in asthma and COPD","volume":"215","author":"Paplinska-Goryca","year":"2020","journal-title":"Clinical Immunology"},{"key":"2025121701301690000_34.178.250110.76","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1080\/15412555.2019.1708296","article-title":"Effects of lung function-related genes and TSLP on COPD phenotypes","volume":"17","author":"Yamada","year":"2020","journal-title":"COPD"},{"key":"2025121701301690000_34.178.250110.77","doi-asserted-by":"publisher","DOI":"10.1152\/ajplung.00045.2007"},{"key":"2025121701301690000_34.178.250110.78","doi-asserted-by":"crossref","first-page":"2301","DOI":"10.1038\/srep02301","article-title":"Thymic stromal lymphopoietin induces migration in human airway smooth muscle cells","volume":"3","author":"Redhu","year":"2013","journal-title":"Sci Rep"},{"key":"2025121701301690000_34.178.250110.79","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1016\/j.jaip.2022.01.040","article-title":"Targeting downstream type 2 cytokines or upstream epithelial alarmins for severe asthma","volume":"10","author":"Chan","year":"2022","journal-title":"J Allergy Clin Immunol Pract"},{"key":"2025121701301690000_34.178.250110.80","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.jaci.2020.12.628","article-title":"IL-25 (IL-17E) in epithelial immunology and pathophysiology","volume":"148","author":"Borowczyk","year":"2021","journal-title":"J Allergy Clin Immunol"},{"key":"2025121701301690000_34.178.250110.81","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20061675"},{"key":"2025121701301690000_34.178.250110.82","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201104-0597OC"},{"key":"2025121701301690000_34.178.250110.83","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0057678"},{"key":"2025121701301690000_34.178.250110.84","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2014.06.035"},{"key":"2025121701301690000_34.178.250110.85","doi-asserted-by":"publisher","DOI":"10.1136\/thoraxjnl-2020-215167"},{"key":"2025121701301690000_34.178.250110.86","doi-asserted-by":"publisher","DOI":"10.1038\/nm.3893"},{"key":"2025121701301690000_34.178.250110.87","doi-asserted-by":"crossref","first-page":"12796","DOI":"10.1038\/s41598-020-68753-1","article-title":"Alteration of immunophenotype of human macrophages and monocytes after exposure to cigarette smoke","volume":"10","author":"da Silva","year":"2020","journal-title":"Sci Rep"},{"key":"2025121701301690000_34.178.250110.88","doi-asserted-by":"publisher","DOI":"10.1136\/thx.2008.108290"},{"key":"2025121701301690000_34.178.250110.89","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1800547"},{"key":"2025121701301690000_34.178.250110.90","doi-asserted-by":"crossref","first-page":"103","DOI":"10.3389\/fcimb.2020.00103","article-title":"Rhinovirus induces basolateral release of IL-17C in highly differentiated airway epithelial cells","volume":"10","author":"Jamieson","year":"2020","journal-title":"Front Cell Infect Microbiol"},{"key":"2025121701301690000_34.178.250110.91","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1080\/15412555.2018.1476475","article-title":"Neutrophilic inflammation in the pathogenesis of chronic obstructive pulmonary disease","volume":"15","author":"Butler","year":"2018","journal-title":"COPD"},{"key":"2025121701301690000_34.178.250110.92","doi-asserted-by":"publisher","DOI":"10.1038\/ni.3443"},{"key":"2025121701301690000_34.178.250110.93","doi-asserted-by":"publisher","DOI":"10.1186\/s12931-016-0428-2"},{"key":"2025121701301690000_34.178.250110.94","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.00974"},{"key":"2025121701301690000_34.178.250110.95","doi-asserted-by":"crossref","first-page":"166","DOI":"10.4046\/trd.2023.0015","article-title":"Chronic obstructive pulmonary disease and the airway microbiome: what respirologists need to know","volume":"86","author":"Sin","year":"2023","journal-title":"Tuberc Respir Dis"},{"key":"2025121701301690000_34.178.250110.96","doi-asserted-by":"publisher","DOI":"10.2147\/COPD.S80091"},{"key":"2025121701301690000_34.178.250110.97","doi-asserted-by":"publisher","DOI":"10.1136\/thoraxjnl-2017-210741"},{"key":"2025121701301690000_34.178.250110.98","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1111\/imm.12937","article-title":"Autoinflammatory disease in the lung","volume":"154","author":"Scambler","year":"2018","journal-title":"Immunology"},{"key":"2025121701301690000_34.178.250110.99","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa032158"},{"key":"2025121701301690000_34.178.250110.100","doi-asserted-by":"publisher","DOI":"10.1183\/16000617.0241-2021"},{"key":"2025121701301690000_34.178.250110.101","doi-asserted-by":"crossref","first-page":"e64689","DOI":"10.1371\/journal.pone.0064689","article-title":"Human neutrophil elastase degrades SPLUNC1 and impairs airway epithelial defense against bacteria","volume":"8","author":"Jiang","year":"2013","journal-title":"PLoS One"},{"key":"2025121701301690000_34.178.250110.102","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.03312-2020"},{"key":"2025121701301690000_34.178.250110.103","doi-asserted-by":"publisher","DOI":"10.1177\/2040622315609251"},{"key":"2025121701301690000_34.178.250110.104","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00162414"},{"key":"2025121701301690000_34.178.250110.105","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2018.04.010"},{"key":"2025121701301690000_34.178.250110.106","doi-asserted-by":"publisher","DOI":"10.1093\/jleuko\/qiae153"},{"key":"2025121701301690000_34.178.250110.107","doi-asserted-by":"publisher","DOI":"10.1111\/all.14661"},{"key":"2025121701301690000_34.178.250110.108","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1016\/j.jaci.2017.04.027","article-title":"Pulmonary inflammation in patients with chronic obstructive pulmonary disease with higher blood eosinophil counts","volume":"140","author":"Kolsum","year":"2017","journal-title":"J Allergy Clin Immunol"},{"key":"2025121701301690000_34.178.250110.109","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.00888"},{"key":"2025121701301690000_34.178.250110.110","doi-asserted-by":"publisher","DOI":"10.1038\/nrd4624"},{"key":"2025121701301690000_34.178.250110.111","doi-asserted-by":"publisher","DOI":"10.1038\/nri3786"},{"key":"2025121701301690000_34.178.250110.112","doi-asserted-by":"publisher","DOI":"10.1172\/JCI10458"},{"key":"2025121701301690000_34.178.250110.113","doi-asserted-by":"publisher","DOI":"10.1186\/1465-9921-8-64"},{"key":"2025121701301690000_34.178.250110.114","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.03.00046402"},{"key":"2025121701301690000_34.178.250110.115","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.01.00229701"},{"key":"2025121701301690000_34.178.250110.116","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.3390\/biomedicines10081949","article-title":"Validation of sputum biomarker immunoassays and cytokine expression profiles in COPD","volume":"10","author":"Mulvanny","year":"2022","journal-title":"Biomedicines"},{"key":"2025121701301690000_34.178.250110.117","doi-asserted-by":"publisher","DOI":"10.1183\/23120541.00870-2023"},{"key":"2025121701301690000_34.178.250110.118","doi-asserted-by":"publisher","DOI":"10.1183\/16000617.0022-2018"},{"key":"2025121701301690000_34.178.250110.119","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.02460-2018"},{"key":"2025121701301690000_34.178.250110.120","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1164\/rccm.202201-0209PP","article-title":"Blood eosinophils and chronic obstructive pulmonary disease: a Global Initiative for Chronic Obstructive Lung Disease Science Committee 2022 review","volume":"206","author":"Singh","year":"2022","journal-title":"Am J Respir Crit Care Med"},{"key":"2025121701301690000_34.178.250110.121","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.06.00072105"},{"key":"2025121701301690000_34.178.250110.122","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1164\/rccm.201912-2384PP","article-title":"Blood eosinophil counts in clinical trials for chronic obstructive pulmonary disease","volume":"202","author":"Singh","year":"2020","journal-title":"Am J Respir Crit Care Med"},{"key":"2025121701301690000_34.178.250110.123","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1186\/s12931-018-0818-8","article-title":"Serum periostin does not reflect type 2-driven inflammation in COPD","volume":"19","author":"Carpaij","year":"2018","journal-title":"Respir Res"},{"key":"2025121701301690000_34.178.250110.124","doi-asserted-by":"crossref","first-page":"23","DOI":"10.2147\/COPD.S94797","article-title":"Association of blood eosinophils and plasma periostin with FEV1 response after 3-month inhaled corticosteroid and long-acting beta2-agonist treatment in stable COPD patients","volume":"11","author":"Park","year":"2015","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"2025121701301690000_34.178.250110.125","doi-asserted-by":"crossref","first-page":"e1112","DOI":"10.1093\/infdis\/jiae232","article-title":"Cytokine biomarkers of exacerbations in sputum from chronic obstructive pulmonary disease patients: a prospective cohort study","volume":"230","author":"Budroni","year":"2024","journal-title":"J Infect Dis"},{"key":"2025121701301690000_34.178.250110.126","doi-asserted-by":"crossref","first-page":"2695","DOI":"10.2147\/COPD.S165780","article-title":"Exhaled nitric oxide in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis","volume":"13","author":"Lu","year":"2018","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"2025121701301690000_34.178.250110.127","doi-asserted-by":"crossref","first-page":"106377","DOI":"10.1016\/j.rmed.2021.106377","article-title":"The role of","volume":"181","author":"Vincken","year":"2021","journal-title":"Respir Med"},{"key":"2025121701301690000_34.178.250110.128","doi-asserted-by":"crossref","first-page":"026007","DOI":"10.1088\/1752-7163\/ab71a4","article-title":"Detection of type2 biomarkers for response in COPD","volume":"14","author":"Yamaji","year":"2020","journal-title":"J Breath Res"},{"key":"2025121701301690000_34.178.250110.129","doi-asserted-by":"crossref","first-page":"e11922","DOI":"10.1097\/MD.0000000000011922","article-title":"Treatment of chronic obstructive pulmonary disease in patients with different fractional exhaled nitric oxide levels","volume":"97","author":"Wu","year":"2018","journal-title":"Medicine"},{"key":"2025121701301690000_34.178.250110.130","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01457-2017"},{"key":"2025121701301690000_34.178.250110.131","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1080\/15412555.2019.1704231","article-title":"Fractional exhaled nitric oxide is associated with the severity of stable COPD","volume":"17","author":"Liu","year":"2020","journal-title":"COPD"},{"key":"2025121701301690000_34.178.250110.132","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1164\/rccm.202110-2353ED","article-title":"Transcriptome-based signatures: the future biomarkers in obstructive pulmonary diseases such as asthma and chronic obstructive pulmonary disease?","volume":"205","author":"van den Berge","year":"2022","journal-title":"Am J Respir Crit Care Med"},{"key":"2025121701301690000_34.178.250110.133","doi-asserted-by":"publisher","DOI":"10.1136\/thoraxjnl-2019-214476"},{"key":"2025121701301690000_34.178.250110.134","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201208-1449OC"},{"key":"2025121701301690000_34.178.250110.135","doi-asserted-by":"publisher","DOI":"10.1136\/thoraxjnl-2012-202878"},{"key":"2025121701301690000_34.178.250110.136","doi-asserted-by":"publisher","DOI":"10.1136\/thx.2008.112433"},{"key":"2025121701301690000_34.178.250110.137","doi-asserted-by":"publisher","DOI":"10.1136\/thorax-2024-BTSabstracts.97"},{"key":"2025121701301690000_34.178.250110.138","doi-asserted-by":"publisher","DOI":"10.1055\/s-0030-1254068"},{"key":"2025121701301690000_34.178.250110.139","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.04590-2020"},{"key":"2025121701301690000_34.178.250110.140","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00633-2019"},{"key":"2025121701301690000_34.178.250110.141","doi-asserted-by":"publisher","DOI":"10.1183\/16000617.0084-2023"},{"key":"2025121701301690000_34.178.250110.142","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01037-2023"},{"key":"2025121701301690000_34.178.250110.143","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00838-2020"},{"key":"2025121701301690000_34.178.250110.144","doi-asserted-by":"crossref","first-page":"3667","DOI":"10.3390\/jcm9113667","article-title":"Periostin and thymic stromal lymphopoietin-potential crosstalk in obstructive airway diseases","volume":"9","author":"Nejman-Gryz","year":"2020","journal-title":"J Clin Med"},{"key":"2025121701301690000_34.178.250110.145","doi-asserted-by":"publisher","DOI":"10.2147\/COPD.S131877"},{"key":"2025121701301690000_34.178.250110.146","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.imlet.2018.01.004","article-title":"Correlation of severity of chronic obstructive pulmonary disease with potential biomarkers","volume":"196","author":"Singh","year":"2018","journal-title":"Immunol Lett"},{"key":"2025121701301690000_34.178.250110.147","doi-asserted-by":"crossref","first-page":"391","DOI":"10.3390\/mi14020391","article-title":"Exhaled biomarkers for point-of-care diagnosis: recent advances and new challenges in breathomics","volume":"14","author":"Kiss","year":"2023","journal-title":"Micromachines"},{"key":"2025121701301690000_34.178.250110.148","first-page":"A6620","article-title":"In the phase 3 Boreas trial, baseline blood eosinophils and baseline fractional exhaled nitric oxide levels predict the response to dupilumab in patients with moderate-to-severe chronic obstructive pulmonary disease and type 2 inflammation","volume":"209","author":"Christenson","year":"2024","journal-title":"Am J Respir Crit Care Med"},{"key":"2025121701301690000_34.178.250110.149","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/j.resinv.2021.01.003","article-title":"Exhaled nitric oxide: a biomarker for chronic obstructive pulmonary disease","volume":"59","author":"Kobayashi","year":"2021","journal-title":"Respir Investig"},{"key":"2025121701301690000_34.178.250110.150","doi-asserted-by":"publisher","DOI":"10.1152\/physrev.00025.2015"},{"key":"2025121701301690000_34.178.250110.151","doi-asserted-by":"publisher","DOI":"10.1136\/thoraxjnl-2018-212271"},{"key":"2025121701301690000_34.178.250110.152","doi-asserted-by":"publisher","DOI":"10.1172\/JCI95693"},{"key":"2025121701301690000_34.178.250110.153","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01448-2018"},{"key":"2025121701301690000_34.178.250110.154","doi-asserted-by":"crossref","first-page":"00606-2021","DOI":"10.1183\/23120541.00606-2021","article-title":"Blood eosinophils to guide inhaled maintenance therapy in a primary care COPD population","volume":"8","author":"Ashdown","year":"2021","journal-title":"ERJ Open Res"},{"key":"2025121701301690000_34.178.250110.155","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2303951"},{"key":"2025121701301690000_34.178.250110.156","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2401304"},{"key":"2025121701301690000_34.178.250110.157","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1056\/NEJMoa1905248","article-title":"Benralizumab for the prevention of COPD exacerbations","volume":"381","author":"Criner","year":"2019","journal-title":"N Engl J Med"},{"key":"2025121701301690000_34.178.250110.158","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/S2213-2600(19)30338-8","article-title":"Predicting response to benralizumab in chronic obstructive pulmonary disease: analyses of GALATHEA and TERRANOVA studies","volume":"8","author":"Criner","year":"2020","journal-title":"Lancet Respir Med"},{"key":"2025121701301690000_34.178.250110.159","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1016\/S2213-2600(21)00167-3","article-title":"Safety and efficacy of itepekimab in patients with moderate-to-severe COPD: a genetic association study and randomised, double-blind, phase 2a trial","volume":"9","author":"Rabe","year":"2021","journal-title":"Lancet Respir Med"},{"key":"2025121701301690000_34.178.250110.160","doi-asserted-by":"crossref","unstructured":"Pandya HC , Guller P , Reid F , et al. FRONTIER-4: a phase 2a study to investigate tozorakimab (anti-IL-33 mAb) in COPD. Eur Respir J 2024; 64: Suppl. 68, OA1964. doi:10.1183\/13993003.congress-2024.OA1964","DOI":"10.1183\/13993003.congress-2024.OA1964"},{"key":"2025121701301690000_34.178.250110.161","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/S2213-2600(21)00556-7","article-title":"Astegolimab, an anti-ST2, in chronic obstructive pulmonary disease (COPD-ST2OP): a phase 2a, placebo-controlled trial","volume":"10","author":"Yousuf","year":"2022","journal-title":"Lancet Respir Med"},{"key":"2025121701301690000_34.178.250110.162","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/S2213-2600(24)00324-2","article-title":"Efficacy and safety of tezepelumab versus placebo in adults with moderate to very severe chronic obstructive pulmonary disease (COURSE): a randomised, placebo-controlled, phase 2a trial","volume":"13","author":"Singh","year":"2025","journal-title":"Lancet Respir Med"},{"key":"2025121701301690000_34.178.250110.163","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1111\/cts.13157","article-title":"Pharmacokinetics and pharmacodynamics of itepekimab in healthy adults and patients with asthma: phase I first-in-human and first-in-patient trials","volume":"15","author":"Kosloski","year":"2022","journal-title":"Clin Transl Sci"},{"key":"2025121701301690000_34.178.250110.164","first-page":"A6989","article-title":"The high affinity anti-IL-33 antibody itepekimab potently blocks IL-33 induced activation of the ST2\/IL-1RAcP signaling complex and inhibits key mediators of airway inflammation","volume":"209","author":"Asrat","year":"2024","journal-title":"Am J Respir Crit Care Med"},{"key":"2025121701301690000_34.178.250110.165","doi-asserted-by":"crossref","first-page":"9825","DOI":"10.1038\/s41598-023-36642-y","article-title":"Tozorakimab (MEDI3506): an anti-IL-33 antibody that inhibits IL-33 signalling via ST2 and RAGE\/EGFR to reduce inflammation and epithelial dysfunction","volume":"13","author":"England","year":"2023","journal-title":"Sci Rep"},{"key":"2025121701301690000_34.178.250110.166","doi-asserted-by":"crossref","first-page":"106175","DOI":"10.1016\/j.rmed.2020.106175","article-title":"COPDCompEx: a novel composite endpoint for COPD exacerbations to enable faster clinical development","volume":"173","author":"Vogelmeier","year":"2020","journal-title":"Respir Med"},{"key":"2025121701301690000_34.178.250110.167","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.02231-2024"},{"key":"2025121701301690000_34.178.250110.168","doi-asserted-by":"crossref","first-page":"A6895","DOI":"10.1164\/ajrccm.2025.211.Abstracts.A6895","article-title":"Structural basis for inhibition of IL-33 induced ST2 activation by astegolimab","volume":"211","author":"Ravala","year":"2025","journal-title":"Am J Respir Crit Care Med"},{"key":"2025121701301690000_34.178.250110.169","unstructured":"Electronic Medicines Compendium . Tezspire (tezepelumab). Summary of Product Characteristics. 2022. Date last accessed: 7 July 2025. www.medicines.org.uk\/emc\/product\/14064\/smpc"},{"key":"2025121701301690000_34.178.250110.170","doi-asserted-by":"publisher","DOI":"10.1183\/23120541.00718-2023"},{"key":"2025121701301690000_34.178.250110.171","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.congress-2023.PA1292"},{"key":"2025121701301690000_34.178.250110.172","unstructured":"ClinicalTrials.gov . Efficacy and safety of tozorakimab in symptomatic chronic obstructive pulmonary disease with a history of exacerbations (OBERON). Date last accessed: 2 April 2025. https:\/\/clinicaltrials.gov\/study\/NCT05166889"},{"key":"2025121701301690000_34.178.250110.173","unstructured":"ClinicalTrials.gov . Efficacy and safety of tozorakimab in symptomatic chronic obstructive pulmonary disease with a history of exacerbations. (TITANIA). Date last accessed: 2 April 2025. https:\/\/clinicaltrials.gov\/study\/NCT05158387"},{"key":"2025121701301690000_34.178.250110.174","unstructured":"ClinicalTrials.gov . Efficacy and safety of tozorakimab in symptomatic chronic obstructive pulmonary disease with a history of exacerbations (MIRANDA) Date last accessed: 2 April 2025. https:\/\/clinicaltrials.gov\/study\/NCT06040086"},{"key":"2025121701301690000_34.178.250110.175","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1708208"},{"key":"2025121701301690000_34.178.250110.176","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.2147\/COPD.S294333","article-title":"Mepolizumab for eosinophil-associated COPD: analysis of METREX and METREO","volume":"16","author":"Pavord","year":"2021","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"2025121701301690000_34.178.250110.177","doi-asserted-by":"publisher","DOI":"10.2147\/COPD.S257474"},{"key":"2025121701301690000_34.178.250110.178","doi-asserted-by":"publisher","DOI":"10.1124\/pharmrev.121.000300"},{"key":"2025121701301690000_34.178.250110.179","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200212-1437OC"},{"key":"2025121701301690000_34.178.250110.180","doi-asserted-by":"publisher","DOI":"10.1016\/j.pupt.2016.05.005"},{"key":"2025121701301690000_34.178.250110.181","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2012.12.019"},{"key":"2025121701301690000_34.178.250110.182","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.2147\/COPD.S428391","article-title":"Can treatable traits be the approach to addressing the complexity and heterogeneity of COPD?","volume":"18","author":"Cazzola","year":"2023","journal-title":"Int J Chron Obstruct Pulmon Dis"}],"container-title":["European Respiratory Review"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1183\/16000617.0110-2025","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,17]],"date-time":"2025-12-17T09:30:35Z","timestamp":1765963835000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.ersnet.org\/lookup\/doi\/10.1183\/16000617.0110-2025"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":182,"journal-issue":{"issue":"178","published-online":{"date-parts":[[2025,12,17]]},"published-print":{"date-parts":[[2025,10]]}},"alternative-id":["10.1183\/16000617.0110-2025"],"URL":"https:\/\/doi.org\/10.1183\/16000617.0110-2025","relation":{},"ISSN":["0905-9180","1600-0617"],"issn-type":[{"value":"0905-9180","type":"print"},{"value":"1600-0617","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10]]}}}